Magnus Financial Group LLC Has $79,000 Stock Position in LifeMD, Inc. (NASDAQ:LFMD)

Magnus Financial Group LLC increased its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 31.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,000 shares of the company’s stock after buying an additional 3,792 shares during the quarter. Magnus Financial Group LLC’s holdings in LifeMD were worth $79,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirador Capital Partners LP raised its position in shares of LifeMD by 139.3% during the fourth quarter. Mirador Capital Partners LP now owns 106,059 shares of the company’s stock worth $525,000 after purchasing an additional 61,731 shares during the period. JPMorgan Chase & Co. raised its holdings in LifeMD by 496.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 88,173 shares of the company’s stock worth $462,000 after buying an additional 73,389 shares during the period. Barclays PLC lifted its stake in LifeMD by 311.7% in the third quarter. Barclays PLC now owns 49,017 shares of the company’s stock valued at $257,000 after buying an additional 37,112 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of LifeMD by 11.4% in the third quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock valued at $4,293,000 after buying an additional 83,598 shares during the period. Finally, XTX Topco Ltd increased its position in shares of LifeMD by 306.8% during the third quarter. XTX Topco Ltd now owns 55,738 shares of the company’s stock worth $292,000 after acquiring an additional 42,037 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors.

Insider Activity at LifeMD

In other news, CEO Justin Schreiber sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $6.52, for a total value of $163,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,728,715 shares of the company’s stock, valued at $17,791,221.80. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 15.97% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on LFMD shares. KeyCorp reduced their target price on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Lake Street Capital initiated coverage on LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Mizuho began coverage on shares of LifeMD in a research note on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, LifeMD currently has an average rating of “Moderate Buy” and an average price target of $11.14.

LifeMD Stock Up 1.6 %

NASDAQ:LFMD opened at $5.16 on Friday. LifeMD, Inc. has a twelve month low of $3.99 and a twelve month high of $12.88. The firm has a market capitalization of $223.48 million, a price-to-earnings ratio of -8.06 and a beta of 1.49. The stock’s 50 day moving average price is $5.45 and its two-hundred day moving average price is $5.42.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). The company had revenue of $53.39 million for the quarter, compared to analyst estimates of $53.53 million. During the same quarter last year, the firm posted ($0.20) EPS. As a group, analysts anticipate that LifeMD, Inc. will post -0.56 earnings per share for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.